The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials

CER6888
2013 Vol.31, N°4 ,Suppl.78
PI 0019, PF 0021
Rheumatoid arthritis

Free to view
(click on article PDF icon to read the article)

PMID: 24129131 [PubMed]

Received: 19/08/2013
Accepted : 26/08/2013
In Press: 03/10/2013
Published: 03/10/2013

Abstract

There has been great interest lately concerning the possibility that in the treatment of rheumatoid arthritis, biologic agents might be withdrawn for patients who achieve desirable targets, such as low disease activity or remission. While there are a number of reasons why such a treatment paradigm might be desirable, there is a paucity of relevant data at present to guide clinicians about embarking on such a treatment change. Data is starting to emerge, much of it from controlled trials, that can provide some guidance as to which patients might be the best candidates for such an approach. These data will provide answers to the key questions that remain concerning this important potential paradigm shift in the treatment of rheumatoid arthritis as well as other systemic inflammatory autoimmune diseases.